Literature DB >> 14642195

Management of Antiretroviral Therapy in Neonates, Children, and Adolescents.

Michael Neely1, Andrea Kovacs.   

Abstract

There have been tremendous advances in the prevention of mother-to-child transmission of HIV and treatment of HIV-infected children and adolescents. Although multiple classes of anti-HIV drugs are available that can control viral replication and stabilize immune function when used in combination, patients and their providers also must manage complex and frequently toxic regimens. This article summarizes official National Institutes of Health guidelines for the prevention of perinatal HIV infection and the management of pediatric and adolescent HIV infection, and provides the most current updates on indications for therapy, recommended first-line therapy, criteria for changing therapy, salvage therapy, and novel management strategies.

Entities:  

Year:  2003        PMID: 14642195     DOI: 10.1007/s11908-003-0097-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  64 in total

Review 1.  Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.

Authors:  Monica Nolan; Mary Glenn Fowler; Lynne M Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-06-01       Impact factor: 3.731

2.  Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution.

Authors:  Homayoun Khanlou; Vijayabhaskar R Kandula; Vivian Yeh; Tomiko G Stein; Susan Sanchez; Juan-Carlos Ricaurte; Laveeza Bhatti; Charles F Farthing; Juan-Carlos Ricuarte
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

3.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

4.  Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.

Authors:  P Palumbo; B Holland; T Dobbs; C P Pau; C C Luo; E J Abrams; S Nesheim; P Vink; R Respess; M Bulterys
Journal:  J Infect Dis       Date:  2001-09-20       Impact factor: 5.226

5.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.

Authors:  M Lallemant; G Jourdain; S Le Coeur; S Kim; S Koetsawang; A M Comeau; W Phoolcharoen; M Essex; K McIntosh; V Vithayasai
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

7.  Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Authors:  Stuart E Starr; Courtney V Fletcher; Stephen A Spector; Richard C Brundage; Florence H Yong; Steven D Douglas; Patricia M Flynn; Mark W Kline
Journal:  Pediatr Infect Dis J       Date:  2002-07       Impact factor: 2.129

Review 8.  Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects.

Authors:  Franco Lori; Andrea Foli; Julianna Lisziewicz
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

9.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

Review 10.  HIV therapy advances. Pediatric antiretroviral choices.

Authors:  S A Spector
Journal:  AIDS       Date:  1994-09       Impact factor: 4.177

View more
  1 in total

Review 1.  Management of antiretroviral therapy in neonates, children, and adolescents.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.